A phase I/IIa, double-blinded, randomised controlled trial to assess the safety, tolerability, and early signs of anti-tumour activity of ITOP1 – a prime/boost viral vector vaccine targeting tumour specific antigens in subjects with surgically resectable oesophageal adenocarcinoma (VISTA)

Principal Investigator

Elizabeth Smyth

Contact us

Email: orh-tr.earlyphasenurses@nhs.net

IRAS number

1008088